Cargando…
Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients
Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson's disease (PD), and orally bioavailable, brain penetrant and highly potent LRRK2 kinase inhibitors are in early stages of clinical testing. Detection of LRRK2 phosphorylation, as well as phosph...
Autores principales: | Fernández, Belén, Lara Ordóñez, Antonio Jesús, Fdez, Elena, Mutez, Eugénie, Comptdaer, Thomas, Leghay, Coline, Kreisler, Alexandre, Simonin, Clémence, Vandewynckel, Laurine, Defebvre, Luc, Destée, Alain, Bleuse, Séverine, Taymans, Jean-Marc, Chartier-Harlin, Marie-Christine, Hilfiker, Sabine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792036/ https://www.ncbi.nlm.nih.gov/pubmed/31527116 http://dx.doi.org/10.1042/BCJ20190315 |
Ejemplares similares
-
Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers
por: Taymans, Jean-Marc, et al.
Publicado: (2023) -
Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells
por: Goveas, Liesel, et al.
Publicado: (2021) -
Protocol to measure centrosome cohesion deficits mediated by pathogenic LRRK2 in cultured cells using confocal microscopy
por: Fdez, Elena, et al.
Publicado: (2023) -
Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation
por: Madero-Pérez, Jesús, et al.
Publicado: (2018) -
Functional Analyses of Two Novel
LRRK2
Pathogenic Variants in Familial Parkinson′s Disease
por: Coku, Ilda, et al.
Publicado: (2022)